Celgene's (CELG) Apremilast anti-inflammatory treatment reduced the symptoms of psoriasis, an...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene's (CELG) Apremilast anti-inflammatory treatment reduced the symptoms of psoriasis, an autoimmune skin disease, by 75% in a third of patients in a Phase III trial. However, that's below the 41% rate in a Phase II study, raising doubts about whether Apremilast will meet Celgene's hopes and become a new blockbuster drug. Apremilast would compete with rival medicines from AbbVie (ABBV) and Amgen (AMGN). (PR)